Six months into a campaign to rout out corruption from the Chinese healthcare industry, many of the underlying issues in the sector remain unchanged.
Last summer, China’s ongoing corruption crackdown found a new target: the healthcare sector.
In an effort to lower medical costs at a time of slowing economic growth, the Chinese government targeted unscrupulous doctors, hospital officials, and pharmaceutical executives.
By mid-August, more than 170 hospital administrators were under investigation, according to state media, a dozen Chinese healthcare companies had withdrawn IPO plans, and $142 billion worth of value in Chinese heal
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Washington’s $370 billion Inflation Reduction Act was seen as a generational opportunity for miners in the U.S. as well as mineral rich trading partners. But almost two years later, the North American mining industry is in crisis and no closer to chipping away at China's dominance. What went wrong?
The academic explains why we need to look beyond the actions of the Chinese government to understand how and why China is shaping countries in the region.
Navigate China's Business Landscape with Confidence.